Tractus Vascular receives 510(k) clearance for its TractusTM CSC
Category: #health  By Mateen Dalal  Date: 2019-11-04
  • share
  • Twitter
  • Facebook
  • LinkedIn

Tractus Vascular receives 510(k) clearance for its TractusTM CSC

Vascular diseases are commonly termed as any abnormal condition that arises in the blood vessels (veins and arteries) which can lead to severe disability or death. Currently, there are several treatment alternatives for this condition, but several pharma companies are still searching for novel breakthroughs for treating this condition. 

Tractus Vascular LLC recently made some strides when it announced receiving a 510(k) clearance for its TractusTM Crossing Support Catheter (CSC) with lengths of 170 cm, 155 cm, 135 cm and 90 cm and with 0.035”, 0.018” and 0.014” guidewire compatibility.

For the record, TractusTM CSC is a highly novel treatment for vascular disease and is built for the purpose of using it during interventional procedures in the coronary and peripheral vasculature to maintain a guidewire as well as access in discrete regions, offer a channel for delivering contrast media and saline solutions, and permit guidewire exchanges.

Moreover, with most CSC being built with a braided sheath, Tractus provides its Jigsaw TechnologyTM laser cut stainless-steel shaft that includes a continuous helical cut pattern developing interlocking teeth.

Speaking on the clearance, Janet Burpee, Chairman and CEO/CTO, Tractus said that obtaining the FDA’s approval marks as one of many milestones in developing market technology that leverages economies in current catheter laboratories while always concentrating on user needs and patient outcomes.

Reportedly, Tractus Vascular was earlier built from an incubator firm, Tinker Med, LLC, which was originally a fully owned subsidiary of Burpee MedSystems, LLC. Commenting on this, Burpee said that, with Burpee MedSystems’ sale, Tinker Med could concentrate more on its firms that include Venarum Medical and Tractus Vascular.

Incidentally, medical device company Medtronic plc has also made significant development in the field of vascular disease when it revealed that it has obtained Breakthrough Device designation for its Valiant® TAAA Stent Graft System from the U.S. FDA. 

Reportedly, the platform is used for repair of TAAA (thoracoabdominal aortic aneurysm), a complex issue that causes bloating of the aorta, that spreads from the chest to the abdomen, with minimally invasion.

Source Credit: https://www.businesswire.com/news/home/20191102005020/en/Tractus-Crossing-Support-Catheter-Jigsaw-TechnologyTM-Receives

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Air France-KLM & JAL make bids to purchase stake in Malaysia Airlines
Air France-KLM & JAL make bids to purchase stake in Malaysia Airlines
By Mateen Dalal

Air France–KLM S.A., one of the leading global air transport players, has reportedly made a proposal to invest in Malaysia Airlines and gain around 49 percent stake. Japan Airlines (JAL) is also looking to acquire a 25 percent stake in Mal...

Accenture opens innovation center in South Beach Road office
Accenture opens innovation center in South Beach Road office
By Mateen Dalal

Accenture, an Irish multinational professional services company, has recently opened a global innovation center within the Accenture’s office at South Beach Road, which is supported by EDB (Economic Development Board) in Singapore. It will pro...

Verrica unveils positive data from VP-102 study in molluscum treatment
Verrica unveils positive data from VP-102 study in molluscum treatment
By Mateen Dalal

Findings from the study are being produced at the 17th Annual Winter Clinical Dermatology Conference in Kohala Coast The data indicated a considerable increase in the percentage of patients with lesion clearance in VP-102 group Verrica Pharmaceu...